Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-06-28
Schrodinger, Inc.
Schrödinger sells computational molecular discovery software and uses the same platform to generate collaboration, milestone, royalty, and selective therapeutics value.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From scientific tool to discovery operating layer
The upside case is a commercial model shift more than a binary drug bet. If AI-driven discovery work increasingly runs through a sticky, paid workflow hub, the company can compound as a better software business while keeping therapeutics upside mostly off balance sheet.

Analysis

Thesis
Schrödinger can roughly triple enterprise value by 2031 if LiveDesign becomes a stickier discovery workflow hub, hosted and throughput pricing capture AI-driven usage growth, and therapeutics upside is monetized through partners rather than rebuilt as a cash-hungry internal pipeline.
Last Economy Alignment
Cheaper cognition and compute should increase demand for molecular design software, and Schrödinger owns a real control point in workflow plus simulation. The main limit is not relevance but value capture: it still must prove that hosted and usage economics scale faster than pharma in-sourcing or good-enough AI substitutes.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
This is mostly a quality-of-revenue rerating, not a moonshot pipeline call. If hosted delivery makes revenue more recurring, Bunsen expands the paid workflow surface, and partnerships keep biology upside off balance sheet, the company can look less like a niche scientific tool and more like a durable discovery operating layer.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not survival but value capture. Schrödinger has enough product depth and liquidity to matter, but it must prove that more AI activity flows through a sticky paid workflow and not into customer-owned stacks, generic models, or lower-value scientific utility economics.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
They control a useful choke point where drug teams store project data, run models, and coordinate outside partners, so more AI can increase activity on their system instead of replacing it. The risk is that big pharma keeps the workflow in-house or cheaper AI tools make them just one engine underneath someone else's interface.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.88
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case